Beth Del Jocco
Vice President of Corporate Affairs at argenx SE
Replay available
argenx SE (ARGX) Q2 2026 Earnings Call
argenx SE (NASDAQ: ARGX) Q2 2026 earnings conference call, held 2026-07-23. Replay captured from the company's public earnings webcast.
Hosted by
Featured presenters
Karen Massey
Chief Executive Officer at argenx SE
Karl Gubitz
Chief Financial Officer at argenx SE
Sandrine Perej Gerard
Chief Commercialization Officer at argenx SE
Luc Troian
Chief Medical Officer at argenx SE
Myles Minter
Derek Archila
Wells Fargo
Tazeen Ahmad
BofA
Investor webinar replay
Watch the replay and follow the connected company analysis, news, and investor updates for Argenx Se.
Replay transcript excerpt
WEBVTT NOTE Transcription provided by Deepgram Request Id: 01a0424b-d035-70d3-ac62-62d4a6e404eb Created: 2026-08-27T08:17:43.595Z Duration: 3674.064 Channels: 1 00:00:00.640 -- 00:00:02.879 Good morning. My name is Leila, and I 00:00:02.879 -- 00:00:04.799 will be your conference operator today. I would 00:00:04.799 -- 00:00:06.480 like to welcome everyone to the call. 00:00:06.879 -- 00:00:08.559 This time, all lines have been placed on 00:00:08.559 -- 00:00:11.120 mute to prevent any background noise. After the 00:00:11.120 -- 00:00:12.799 speakers' remarks, there will be a question and 00:00:12.799 -- 00:00:15.405 answer session. Thank you. I'd like to introduce 00:00:15.405 -- 00:00:18.045 Beth Del Jocco, Vice President of Corporate Affairs. 00:00:18.045 -- 00:00:19.404 You may now begin your call. 00:00:20.445 -- 00:00:23.564 Thank you. A press release was issued earlier 00:00:23.564 -- 00:00:26.125 today with our second quarter twenty twenty six 00:00:26.125 -- 00:00:28.205 financial results and business update. 00:00:28.640 -- 00:00:30.640 This can be found on our website along 00:00:30.640 -- 00:00:33.120 with the presentation for today's webcast. 00:00:33.360 -- 00:00:35.920 Before we begin, on Slide two, I'd like 00:00:35.920 -- 00:00:38.079 to remind you that forward looking statements may 00:00:38.079 -- 00:00:40.720 be presented during this call. These may include 00:00:40.720 -- 00:00:43.440 statements about our future expectations, clinical developments, 00:00:43.875 -- 00:00:46.435 regulatory timelines, the potential success of our product 00:00:46.435 -- 00:00:49.875 candidates, financial projections and upcoming milestones. 00:00:50.355 -- 00:00:53.235 Actual results may differ materially from those indicated 00:00:53.235 -- 00:00:54.275 by these st...